You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethocarbamol
Accession NumberDB00423  (APRD01102)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206)
Structure
Thumb
Synonyms
(RS)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate
Delaxin
Methocarbamol
Méthocarbamol
Methocarbamolum
Metocarbamol
Metocarbamolo
Robaxin
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Methocarbamol Inj 100mg/mlliquid100 mgintramuscular; intravenousUnivet Pharmaceuticals Ltd.1988-12-31Not applicableCanada
Methocarbamol Omegaliquid100 mgintramuscular; intravenousOmega Laboratories Ltd2003-07-28Not applicableCanada
PMS-methocarbamol Inj 100mg/mlliquid100 mgintramuscular; intravenousPharmascience Inc1990-12-31Not applicableCanada
Robaximol Inj 100mg/mlliquid100 mgintramuscular; intravenousMontreal Veterinary Products Inc.1989-12-31Not applicableCanada
Robaxininjection100 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.1959-06-16Not applicableUs
Robaxintablet, film coated750 mg/1oralActient Pharmaceuticals, LLC2011-08-18Not applicableUs
Robaxintablet, film coated750 mg/1oralSTAT Rx USA LLC2003-01-20Not applicableUs
Robaxintablet, film coated750 mg/1oralPd Rx Pharmaceuticals, Inc.2003-01-20Not applicableUs
Robaxintablet500 mg/1oralREMEDYREPACK INC.2012-08-16Not applicableUs
Robaxintablet, film coated500 mg/1oralActient Pharmaceuticals, LLC2012-05-15Not applicableUs
Robaxin Inj 100mg/mlliquid100 mgintramuscular; intravenousAyerst Laboratories1992-12-311997-08-15Canada
Robaxin Injectable Liq 100mg/mlliquid100 mgintramuscular; intravenousWyeth Ayerst Canada Inc.1996-10-252000-03-07Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Methocarbamoltablet500 mg/1oralREMEDYREPACK INC.2012-07-10Not applicableUs
Methocarbamoltablet500 mg/1oralA S Medication Solutions Llc2000-01-01Not applicableUs
Methocarbamoltablet, film coated750 mg/1oralGolden State Medical Supply, Inc.2014-02-20Not applicableUs
Methocarbamoltablet750 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2003-01-29Not applicableUs
Methocarbamoltablet750 mg/1oralPreferred Pharmaceuticals, Inc.2010-08-06Not applicableUs
Methocarbamoltablet500 mg/1oralWatson Laboratories, Inc.1987-11-01Not applicableUs
Methocarbamoltablet750 mg/1oralClinical Solutions Wholesale, Llc2013-03-20Not applicableUs
Methocarbamoltablet750 mg/1oralRebel Distributors Corp.1976-08-18Not applicableUs
Methocarbamoltablet500 mg/1oralSTAT Rx USA LLC1987-11-01Not applicableUs
Methocarbamoltablet500 mg/1oralSolco Healthcare US LLC2013-01-15Not applicableUs
Methocarbamoltablet500 mg/1oralREMEDYREPACK INC.2014-01-08Not applicableUs
Methocarbamoltablet750 mg/1oralCardinal Health2007-07-09Not applicableUs
Methocarbamoltablet750 mg/1oralProficient Rx LP2013-03-20Not applicableUs
Methocarbamoltablet750 mg/1oralAphena Pharma Solutions Tennessee, Inc.2000-01-01Not applicableUs
Methocarbamoltablet500 mg/1oralWest Ward Pharmaceuticals Corp2000-01-01Not applicableUs
Methocarbamoltablet, film coated750 mg/1oralVirtus Pharmaceuticals2013-12-15Not applicableUs
Methocarbamoltablet750 mg/1oralBlenheim Pharmacal, Inc.2000-01-01Not applicableUs
Methocarbamoltablet750 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2000-01-01Not applicableUs
Methocarbamoltablet500 mg/1oralDispensing Solutions, Inc.2000-01-01Not applicableUs
Methocarbamoltablet500 mg/1oralAvera Mc Kennan Hospital2015-09-30Not applicableUs
Methocarbamoltablet500 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-01-09Not applicableUs
Methocarbamoltablet500 mg/1oralCamber Pharmaceuticals, Inc.2013-03-20Not applicableUs
Methocarbamoltablet500 mg/1oralPd Rx Pharmaceuticals, Inc.2000-01-01Not applicableUs
Methocarbamoltablet750 mg/1oralAv Pak2014-10-20Not applicableUs
Methocarbamoltablet500 mg/1oralPhysicians Total Care, Inc.2009-07-21Not applicableUs
Methocarbamoltablet750 mg/1oralREMEDYREPACK INC.2015-12-24Not applicableUs
Methocarbamoltablet500 mg/1oralClinical Solutions Wholesale2000-01-01Not applicableUs
Methocarbamoltablet750 mg/1oralbryant ranch prepack2003-01-29Not applicableUs
Methocarbamoltablet750 mg/1oralKeltman Pharmaceuticals Inc.2007-07-25Not applicableUs
Methocarbamoltablet500 mg/1oralKAISER FOUNDATION HOSPITALS2015-06-04Not applicableUs
Methocarbamoltablet, film coated500 mg/1oralCarilion Materials Management2013-12-15Not applicableUs
Methocarbamoltablet500 mg/1oralSTAT Rx USA LLC2000-01-01Not applicableUs
Methocarbamoltablet750 mg/1oralRebel Distributors Corp2010-03-01Not applicableUs
Methocarbamoltablet500 mg/1oralREMEDYREPACK INC.2013-09-27Not applicableUs
Methocarbamoltablet750 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Methocarbamoltablet500 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-16Not applicableUs
Methocarbamoltablet750 mg/1oralA S Medication Solutions Llc2000-01-01Not applicableUs
Methocarbamoltablet500 mg/1oralGolden State Medical Supply, Inc.2015-01-13Not applicableUs
Methocarbamoltablet500 mg/1oralHetero Drugs Limited Unit III2009-11-06Not applicableUs
Methocarbamoltablet750 mg/1oralPreferred Pharmaceuticals, Inc.2014-11-25Not applicableUs
Methocarbamoltablet750 mg/1oralWatson Laboratories, Inc.1987-11-01Not applicableUs
Methocarbamoltablet750 mg/1oralREMEDYREPACK INC.2013-04-022016-03-12Us
Methocarbamoltablet750 mg/1oralPd Rx Pharmaceuticals, Inc.2003-01-29Not applicableUs
Methocarbamoltablet750 mg/1oralSolco Healthcare US LLC2013-01-15Not applicableUs
Methocarbamoltablet750 mg/1oralREMEDYREPACK INC.2015-06-22Not applicableUs
Methocarbamoltablet500 mg/1oralCardinal Health2007-07-03Not applicableUs
Methocarbamoltablet500 mg/1oralProficient Rx LP2013-03-20Not applicableUs
Methocarbamoltablet500 mg/1oralAphena Pharma Solutions Tennessee, Inc.2000-01-01Not applicableUs
Methocarbamoltablet750 mg/1oralWest Ward Pharmaceuticals Corp2000-01-01Not applicableUs
Methocarbamoltablet500 mg/1oralAmerican Health Packaging2013-05-062015-12-29Us
Methocarbamoltablet750 mg/1oralBlenheim Pharmacal, Inc.2014-01-22Not applicableUs
Methocarbamoltablet500 mg/1oralLake Erie Medical DBA Quality Care Products LLC2003-01-29Not applicableUs
Methocarbamoltablet750 mg/1oralPhysicians Total Care, Inc.2003-07-14Not applicableUs
Methocarbamoltablet500 mg/1oralDIRECT RX2015-01-01Not applicableUs
Methocarbamoltablet750 mg/1oralContract Pharmacy Services Pa2000-01-01Not applicableUs
Methocarbamoltablet, film coated500 mg/1oralVirtus Pharmaceuticals2015-07-13Not applicableUs
Methocarbamoltablet750 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-01-29Not applicableUs
Methocarbamoltablet750 mg/1oralCamber Pharmaceuticals, Inc.2013-03-20Not applicableUs
Methocarbamoltablet500 mg/1oralPd Rx Pharmaceuticals, Inc.2000-01-01Not applicableUs
Methocarbamoltablet500 mg/1oralUnit Dose Services2000-01-01Not applicableUs
Methocarbamoltablet500 mg/1oralREMEDYREPACK INC.2012-03-12Not applicableUs
Methocarbamoltablet500 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Methocarbamoltablet750 mg/1oralClinical Solutions Wholesale2003-01-29Not applicableUs
Methocarbamoltablet750 mg/1oralbryant ranch prepack2003-01-29Not applicableUs
Methocarbamoltablet500 mg/1oralKeltman Pharmaceuticals Inc.2009-05-08Not applicableUs
Methocarbamoltablet500 mg/1oralKAISER FOUNDATION HOSPITALS2008-08-02Not applicableUs
Methocarbamoltablet750 mg/1oralCardinal Health2013-06-26Not applicableUs
Methocarbamoltablet750 mg/1oralSTAT Rx USA LLC2000-01-01Not applicableUs
Methocarbamoltablet500 mg/1oralRebel Distributors Corp2010-03-01Not applicableUs
Methocarbamoltablet750 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-11-16Not applicableUs
Methocarbamoltablet500 mg/1oralA S Medication Solutions Llc2000-01-01Not applicableUs
Methocarbamoltablet750 mg/1oralGolden State Medical Supply, Inc.2015-01-13Not applicableUs
Methocarbamoltablet750 mg/1oralHetero Drugs Limited Unit III2009-11-06Not applicableUs
Methocarbamoltablet500 mg/1oralPreferred Pharmaceuticals, Inc.2014-11-18Not applicableUs
Methocarbamoltablet500 mg/1oralQualitest Pharmaceuticals2003-01-29Not applicableUs
Methocarbamoltablet500 mg/1oralREMEDYREPACK INC.2015-06-02Not applicableUs
Methocarbamoltablet500 mg/1oralPd Rx Pharmaceuticals, Inc.2003-01-29Not applicableUs
Methocarbamoltablet750 mg/1oralLake Erie Medical DBA Quality Care Products LLC2003-01-29Not applicableUs
Methocarbamoltablet750 mg/1oralMedsource Pharmaceuticals2013-01-15Not applicableUs
Methocarbamoltablet750 mg/1oralH.J. Harkins Company, Inc.1987-11-01Not applicableUs
Methocarbamoltablet750 mg/1oralPd Rx Pharmaceuticals, Inc.1987-11-01Not applicableUs
Methocarbamoltablet750 mg/1oralProficient Rx LP2013-01-15Not applicableUs
Methocarbamoltablet500 mg/1oralAmerican Health Packaging2013-06-26Not applicableUs
Methocarbamoltablet500 mg/1oralKAISER FOUNDATION HOSPITALS2011-06-06Not applicableUs
Methocarbamoltablet750 mg/1oralAmerican Health Packaging2013-05-062015-12-29Us
Methocarbamoltablet750 mg/1oralBlenheim Pharmacal, Inc.2014-01-13Not applicableUs
Methocarbamoltablet750 mg/1oralUnit Dose Services2000-01-01Not applicableUs
Methocarbamoltablet500 mg/1oralCardinal Health2003-01-29Not applicableUs
Methocarbamoltablet750 mg/1oralDIRECT RX2015-01-01Not applicableUs
Methocarbamoltablet750 mg/1oralContract Pharmacy Services Pa2010-03-01Not applicableUs
Methocarbamoltablet, film coated750 mg/1oralVirtus Pharmaceuticals2015-07-13Not applicableUs
Methocarbamoltablet500 mg/1oralMajor Pharmaceuticals1976-08-11Not applicableUs
Methocarbamoltablet750 mg/1oralAidarex Pharmaceuticals LLC2000-01-01Not applicableUs
Methocarbamoltablet750 mg/1oralAphena Pharma Solutions Tennessee, Llc2003-01-29Not applicableUs
Methocarbamoltablet750 mg/1oralREMEDYREPACK INC.2012-03-27Not applicableUs
Methocarbamoltablet750 mg/1oralA S Medication Solutions Llc2000-01-01Not applicableUs
Methocarbamoltablet, film coated500 mg/1oralGolden State Medical Supply, Inc.2014-02-20Not applicableUs
Methocarbamoltablet500 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2003-01-29Not applicableUs
Methocarbamoltablet500 mg/1oralPreferred Pharmaceuticals, Inc.2010-08-06Not applicableUs
Methocarbamoltablet500 mg/1oralLiberty Pharmaceuticals, Inc.2003-01-29Not applicableUs
Methocarbamoltablet500 mg/1oralClinical Solutions Wholesale, Llc2013-03-20Not applicableUs
Methocarbamoltablet500 mg/1oralRebel Distributors Corp.2000-01-01Not applicableUs
Methocarbamoltablet750 mg/1oralSTAT Rx USA LLC1987-11-01Not applicableUs
Methocarbamoltablet500 mg/1oralREMEDYREPACK INC.2013-01-19Not applicableUs
Methocarbamoltablet750 mg/1oralPd Rx Pharmaceuticals, Inc.2000-01-01Not applicableUs
Methocarbamoltablet500 mg/1oralAv Pak2014-10-20Not applicableUs
Methocarbamoltablet750 mg/1oralA S Medication Solutions Llc2000-01-01Not applicableUs
Methocarbamoltablet500 mg/1oralREMEDYREPACK INC.2014-10-13Not applicableUs
Methocarbamoltablet750 mg/1oralDispensing Solutions, Inc.2003-01-29Not applicableUs
Methocarbamoltablet750 mg/1oralPreferred Pharmaceuticals Inc.2015-08-20Not applicableUs
Methocarbamoltablet750 mg/1oralQualitest Pharmaceuticals2003-01-29Not applicableUs
Methocarbamoltablet750 mg/1oralAmerican Health Packaging2013-06-26Not applicableUs
Methocarbamoltablet750 mg/1oralKAISER FOUNDATION HOSPITALS2011-06-07Not applicableUs
Methocarbamoltablet750 mg/1oralBlenheim Pharmacal, Inc.2016-01-07Not applicableUs
Methocarbamoltablet500 mg/1oralBlenheim Pharmacal, Inc.2014-01-22Not applicableUs
Methocarbamoltablet500 mg/1oralLake Erie Medical DBA Quality Care Products LLC2013-03-20Not applicableUs
Methocarbamoltablet500 mg/1oralREMEDYREPACK INC.2011-07-122016-03-17Us
Methocarbamoltablet500 mg/1oralH.J. Harkins Company, Inc.1987-11-01Not applicableUs
Methocarbamoltablet500 mg/1oralPd Rx Pharmaceuticals, Inc.2010-03-01Not applicableUs
Methocarbamoltablet500 mg/1oralbryant ranch prepack2010-03-01Not applicableUs
Methocarbamoltablet750 mg/1oralNorthwind Pharmaceuticals, LLC2014-09-23Not applicableUs
Methocarbamoltablet750 mg/1oralCardinal Health2003-01-29Not applicableUs
Methocarbamoltablet, film coated750 mg/1oralDIRECT RX2015-01-01Not applicableUs
Methocarbamolinjection, solution100 mg/mLintramuscular; intravenousMylan Institutional LLC2014-12-05Not applicableUs
Methocarbamoltablet, film coated500 mg/1oralVirtus Pharmaceuticals2013-12-15Not applicableUs
Methocarbamoltablet750 mg/1oralMajor Pharmaceuticals1976-08-18Not applicableUs
Methocarbamoltablet500 mg/1oralAidarex Pharmaceuticals LLC2000-01-01Not applicableUs
Methocarbamoltablet500 mg/1oralAphena Pharma Solutions Tennessee, Llc2003-01-29Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Robaxintablet500 mgoralPfizer Consumer Healthcare A Division Of Pfizer Canada Inc1958-12-31Not applicableCanada
Robaxin 750tablet750 mgoralPfizer Consumer Healthcare A Division Of Pfizer Canada Inc1993-12-31Not applicableCanada
Unapproved/Other Products Not Available
International Brands
NameCompany
BolaxinYing Yuan
CarbaflexPaill
DelaxinNot Available
DoloVisanDr.Kade Pharmaceutische Fabrik
FubaxinGrape King
LumirelaxJuvise
MetocarbamolAZ Pharma
MioflexLabinco
MiorelCheminter
MusxanPharmasant
OrtotonRecordati
RebamolWinston
Robaxin-750Pfizer
RobinaxKhandelwal
SinaxarArmofar
TaspanHonten
Brand mixtures
NameLabellerIngredients
A.S.A. With Methocarbamol Night-time Extra StrengthPharmetics (2011) Inc
Acetaminophen 325mg + Methocarbamol 400mg CapletsInternational Pharmaceutical Generics Ltd
Acetaminophen 500mg + Methocarbamol 400mg Extra Strength CapletsInternational Pharmaceutical Generics Ltd
Advil Back PainPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Analgesic and Muscle RelaxantPharmascience Inc
Analgesic and Muscle Relaxant CapletsTeva Canada Limited
Aspirin BackacheBayer Inc Consumer Care
Aspirin Night-timeBayer Inc Consumer Care
Axacet-C1/8Technilab Pharma Inc.
Axisal-C1/8Technilab Pharma Inc.
AxumTeva Canada Limited
Dodd's Back-ease Muscle Spasm and Back Pain ReliefStella Pharmaceutical Canada Inc.
Dodd's Extra Strength Back-easeStella Pharmaceutical Canada Inc.
Douleurs Musculaires Et Les Courbatures Extra Fort/muscle and Back Pain Relief Extra StrengthProdemdis Enr.
Extra Strength Aspirin BackacheBayer Inc Consumer Care
Extra Strength Back PainPharmetics (2011) Inc
Extra Strength Body Pain NightPharmetics (2011) Inc
Extra Strength Muscle & Back Pain Asa 500 Mg Methocarbamol 400 Mg & Acetylsalicylic Acid 500 mgVita Health Products Inc
Extra Strength Muscle & Back Pain ReliefVita Health Products Inc
Extra Strength Muscle & Back Pain Relief With AsaVita Health Products Inc
Extra Strength Tylenol Back PainMcneil Consumer Healthcare Division Of Johnson & Johnson Inc
Extra Strength Tylenol Body Pain NightMcneil Consumer Healthcare Division Of Johnson & Johnson Inc
Ibuprofen+methocarbamol CapletsInternational Pharmaceutical Generics Ltd
MethoxacetTeva Canada Limited
Methoxacet Extra StrengthTeva Canada Limited
Methoxacet-C 1/8Teva Canada Limited
MethoxisalRougier Pharma Division Of Ratiopharm Inc
Methoxisal Extra StrengthTeva Canada Limited
Methoxisal-C 1/2Teva Canada Limited
Methoxisal-C 1/4Teva Canada Limited
Methoxisal-C 1/8Teva Canada Limited
Midol Night-timeBayer Inc Consumer Care
Motrin Platinum Muscle and BodyMcneil Consumer Healthcare Division Of Johnson & Johnson Inc
Muscle & Back Pain Asa 325 Mg Methocarbamol 400 Mg & Acetylsalicylic Acid 325 mgVita Health Products Inc
Muscle & Back Pain ReliefPendopharm Division Of De Pharmascience Inc
Muscle & Back Pain Relief - 8Vita Health Products Inc
Muscle & Back Pain Relief CapletsJamp Pharma Corporation
Muscle & Back Pain Relief Extra StrengthPendopharm Division Of De Pharmascience Inc
Muscle & Back Pain Relief With IbuprofenTeva Canada Limited
Muscle & Back Pain Relief-8Pharmascience Inc
Muscle and Back Pain Platinum ReliefVita Health Products Inc
Muscle and Back Pain ReliefPendopharm Division Of De Pharmascience Inc
Muscle and Back Pain Relief - 8 TabletsPharmetics (2011) Inc
Muscle and Back Pain Relief CapletsJamp Pharma Corporation
Muscle and Back Pain Relief Extra StrengthPendopharm Division Of De Pharmascience Inc
Muscle and Back Pain Relief Regular Strength TabletsPharmetics (2011) Inc
Muscle and Back Pain Relief With AsaTechnilab Pharma Inc.
Muscle and Back Pain Relief With Asa Extra StrengthTechnilab Pharma Inc.
Muscle and Back Pain Relief-8Teva Canada Limited
Muscle Relaxant and AnalgesicTechnilab Pharma Inc.
Muscle Relaxant and Analgesic CapletsInternational Pharmaceutical Generics Ltd
Muscle Relaxant and Back Pain Relief Extra Strength TabletsPharmetics (2011) Inc
Muscle Relaxant and Back Pain Relief Regular Strength TabletsPharmetics (2011) Inc
Nighttime Body PainVita Health Products Inc
Platinum Muscle and Back Pain ReliefVita Health Products Inc
Regular Strength Analgesic & Muscle Relaxant CapletsTeva Canada Limited
Regular Strength Tylenol Back PainMcneil Consumer Healthcare Division Of Johnson & Johnson Inc
Regular Strength Tylenol Body Pain NightMcneil Consumer Healthcare Division Of Johnson & Johnson Inc
Relaxophen CapletsTanta Pharmaceuticals Inc
Robax PlatinumPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
RobaxacetPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Robaxacet Extra StrengthPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Robaxacet TabletsWyeth Consumer Healthcare Inc.
Robaxacet-8Pfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Robaxisal C 1/2Pfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Robaxisal C 1/4Pfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Robaxisal C-1/8 TabletsWyeth Consumer Healthcare Inc.
Robaxisal CapletsWyeth Consumer Healthcare Inc.
Robaxisal Extra StrengthPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Robaxisal TabletsWyeth Consumer Healthcare Inc.
Soulagement Des Douleurs Musculaires & Courbatures Extra FortPharmalab Inc.
Spasmhalt-8Pendopharm Division Of De Pharmascience Inc
Spasmhalt-asa-8Pendopharm Division Of De Pharmascience Inc
Summit UltraPendopharm Division Of De Pharmascience Inc
Super Extra Strength Aspirin BackacheBayer Inc Consumer Care
SaltsNot Available
Categories
UNII125OD7737X
CAS number532-03-6
WeightAverage: 241.2405
Monoisotopic: 241.095022595
Chemical FormulaC11H15NO5
InChI KeyInChIKey=GNXFOGHNGIVQEH-UHFFFAOYSA-N
InChI
InChI=1S/C11H15NO5/c1-15-9-4-2-3-5-10(9)16-6-8(13)7-17-11(12)14/h2-5,8,13H,6-7H2,1H3,(H2,12,14)
IUPAC Name
2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate
SMILES
COC1=CC=CC=C1OCC(O)COC(N)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenol ethers
Direct ParentAnisoles
Alternative Parents
Substituents
  • Anisole
  • Alkyl aryl ether
  • Secondary alcohol
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor use as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions.
PharmacodynamicsMethocarbamol is a central muscle relaxant for skeletal muscles, used to treat spasms. It is structurally related to guaifenesin. Methocarbamol's exact mechanism of causing skeletal muscle relaxation is unknown. It is thought to work centrally, perhaps by general depressant effects. It has no direct relaxant effects on striated muscle, nerve fibers, or the motor endplate. It will not directly relax contracted skeletal muscles. The drug has a secondary sedative effect.
Mechanism of actionThe mechanism of action of methocarbamol in humans has not been established, but may be due to central nervous system depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.
Related Articles
AbsorptionRapid. Onset of action is about 30 minutes after oral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationSmall amounts of unchanged methocarbamol also are excreted in the urine.
Half life1.14-1.24 hours
Clearance
  • 0.2 – 0.8 L/h/kg [healthy]
ToxicitySymptoms of overdose include blurred vision, coma, drowsiness, low blood pressure, nausea, and seizures.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9638
Blood Brain Barrier+0.5747
Caco-2 permeable-0.6689
P-glycoprotein substrateNon-substrate0.6452
P-glycoprotein inhibitor INon-inhibitor0.9411
P-glycoprotein inhibitor IINon-inhibitor0.8887
Renal organic cation transporterNon-inhibitor0.9105
CYP450 2C9 substrateNon-substrate0.8431
CYP450 2D6 substrateNon-substrate0.7658
CYP450 3A4 substrateNon-substrate0.606
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9302
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9066
CYP450 3A4 inhibitorNon-inhibitor0.9338
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9542
Ames testNon AMES toxic0.5776
CarcinogenicityNon-carcinogens0.9406
BiodegradationNot ready biodegradable0.8358
Rat acute toxicity2.2930 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.984
hERG inhibition (predictor II)Non-inhibitor0.9411
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Marsam pharmaceuticals llc
  • Watson laboratories inc
  • Baxter healthcare corp anesthesia critical care
  • Ferndale laboratories inc
  • Forest laboratories inc
  • Able laboratories inc
  • American therapeutics inc
  • Ascot hosp pharmaceuticals inc div travenol laboratories inc
  • Clonmel healthcare ltd
  • Heather drug co inc
  • Hetero drugs ltd
  • Impax laboratories inc
  • Inwood laboratories inc sub forest laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Lannett co inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Nylos trading co inc
  • Pharmeral inc
  • Pioneer pharmaceuticals inc
  • Purepac pharmaceutical co
  • Roxane laboratories inc
  • Sandoz inc
  • Solco healthcare us llc
  • Solvay pharmaceuticals
  • Superpharm corp
  • Tablicaps inc
  • Upsher smith laboratories inc
  • Vintage pharmaceuticals inc
  • West ward pharmaceutical corp
  • Schwarz pharma inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionintramuscular; intravenous100 mg/mL
Tabletoral500 mg/1
Tabletoral750 mg/1
Liquidintramuscular; intravenous100 mg
Tabletoral
Injectionintramuscular; intravenous100 mg/mL
Tabletoral500 mg
Tablet, film coatedoral500 mg/1
Tablet, film coatedoral750 mg/1
Tabletoral750 mg
Prices
Unit descriptionCostUnit
Robaxin-750 750 mg tablet2.48USD tablet
Robaxin 100 mg/ml vial2.2USD ml
Robaxin-750 tablet1.99USD tablet
Robaxin 500 mg tablet1.68USD tablet
Methocarbamol powder0.95USD g
Methocarbamol 750 mg tablet0.49USD tablet
Methocarbamol 500 mg tablet0.38USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point93 °CPhysProp
water solubility7200 mg/L (at 25 °C)CHEM INSPECT TEST INST (1992)
logP0.61CHEM INSPECT TEST INST (1992)
Predicted Properties
PropertyValueSource
Water Solubility4.21 mg/mLALOGPS
logP0.63ALOGPS
logP0.45ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)13.6ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area91.01 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity59.07 m3·mol-1ChemAxon
Polarizability24.28 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Sica DA, Comstock TJ, Davis J, Manning L, Powell R, Melikian A, Wright G: Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals. Eur J Clin Pharmacol. 1990;39(2):193-4. [PubMed:2253675 ]
External Links
ATC CodesM03BA53M03BA03M03BA73
AHFS Codes
  • 12:20.00
PDB EntriesNot Available
FDA labelDownload (121 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Methocarbamol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Methocarbamol.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Methocarbamol.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Methocarbamol.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Methocarbamol.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Methocarbamol.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Methocarbamol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Methocarbamol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methocarbamol.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Methocarbamol.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Methocarbamol.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methocarbamol.
AmoxapineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Methocarbamol.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methocarbamol.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Methocarbamol.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Methocarbamol.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Methocarbamol.
AzelastineMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Methocarbamol.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Methocarbamol.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Methocarbamol.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Methocarbamol.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Methocarbamol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.
BrimonidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methocarbamol.
BrompheniramineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Methocarbamol.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methocarbamol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Methocarbamol.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Methocarbamol.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methocarbamol.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Methocarbamol.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Methocarbamol.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Methocarbamol.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Methocarbamol.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methocarbamol.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methocarbamol.
CarbinoxamineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Methocarbamol.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Methocarbamol.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Methocarbamol.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Methocarbamol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methocarbamol.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Methocarbamol.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Methocarbamol.
ChlorphenamineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methocarbamol.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methocarbamol.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Methocarbamol.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methocarbamol.
CitalopramThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Methocarbamol.
ClidiniumThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Methocarbamol.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Methocarbamol.
ClomipramineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methocarbamol.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Methocarbamol.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Methocarbamol.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methocarbamol.
CyclizineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methocarbamol.
CyproheptadineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methocarbamol.
DapoxetineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Methocarbamol.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Methocarbamol.
DesipramineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Methocarbamol.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methocarbamol.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methocarbamol.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Methocarbamol.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methocarbamol.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Methocarbamol.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Methocarbamol.
DifenoxinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methocarbamol.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methocarbamol.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methocarbamol.
DimenhydrinateThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methocarbamol.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methocarbamol.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Methocarbamol.
DoxepinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.
DoxylamineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Methocarbamol.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Methocarbamol.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Methocarbamol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methocarbamol.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Methocarbamol.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Methocarbamol.
EfavirenzThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Methocarbamol.
EntacaponeThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Entacapone.
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Methocarbamol.
EscitalopramThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Methocarbamol.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methocarbamol.
EthanolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Methocarbamol.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methocarbamol.
EthosuximideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Methocarbamol.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Methocarbamol.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methocarbamol.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Methocarbamol.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Methocarbamol.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Methocarbamol.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methocarbamol.
EtoperidoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Methocarbamol.
EzogabineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methocarbamol.
FenfluramineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methocarbamol.
FexofenadineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Methocarbamol.
FlunarizineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Methocarbamol.
FluoxetineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methocarbamol.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methocarbamol.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methocarbamol.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Methocarbamol.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Methocarbamol.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methocarbamol.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Methocarbamol is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Methocarbamol.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Methocarbamol.
GuanfacineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Methocarbamol.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methocarbamol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Methocarbamol.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Methocarbamol.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Methocarbamol.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methocarbamol.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methocarbamol.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.
HydroxyzineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Indalpine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Methocarbamol.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Methocarbamol.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Methocarbamol.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Methocarbamol.
LamotrigineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Methocarbamol.
LevocabastineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methocarbamol.
LevomilnacipranThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methocarbamol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Methocarbamol.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Methocarbamol.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Methocarbamol.
LoratadineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methocarbamol.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methocarbamol.
Lu AA21004The risk or severity of adverse effects can be increased when Methocarbamol is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methocarbamol.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Methocarbamol.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Methocarbamol.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Methocarbamol.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methocarbamol.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methocarbamol.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methocarbamol.
MetaxaloneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Methocarbamol.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Methocarbamol.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Methocarbamol.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Methocarbamol.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Methocarbamol.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methocarbamol.
MethsuximideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methocarbamol.
MetyrosineMethocarbamol may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Methocarbamol.
MilnacipranThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.
MirtazapineMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Methocarbamol.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Methocarbamol.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methocarbamol.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.
NabiloneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methocarbamol.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methocarbamol.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Methocarbamol.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Methocarbamol.
NortriptylineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methocarbamol.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Methocarbamol.
OrphenadrineMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Methocarbamol.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Methocarbamol.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methocarbamol.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methocarbamol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Methocarbamol.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methocarbamol.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methocarbamol.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methocarbamol.
ParaldehydeMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Methocarbamol.
ParoxetineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methocarbamol.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methocarbamol.
PerampanelThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Methocarbamol.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methocarbamol.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Methocarbamol.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methocarbamol.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Methocarbamol.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Methocarbamol.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Methocarbamol.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Methocarbamol.
PipotiazineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pomalidomide.
PramipexoleMethocarbamol may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Methocarbamol.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Methocarbamol.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methocarbamol.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Methocarbamol.
PrimidoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Methocarbamol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methocarbamol.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Methocarbamol.
PromethazineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methocarbamol.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Methocarbamol.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Methocarbamol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Methocarbamol.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Methocarbamol.
PyridostigmineThe therapeutic efficacy of Pyridostigmine can be decreased when used in combination with Methocarbamol.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Methocarbamol.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methocarbamol.
RamelteonThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ramelteon.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methocarbamol.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methocarbamol.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methocarbamol.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methocarbamol.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Methocarbamol.
RopiniroleMethocarbamol may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methocarbamol.
RotigotineMethocarbamol may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methocarbamol.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Methocarbamol.
ScopolamineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methocarbamol.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Methocarbamol.
SertralineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methocarbamol.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Methocarbamol.
StiripentolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methocarbamol.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methocarbamol.
SuvorexantThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Methocarbamol.
TetrabenazineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Methocarbamol.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Methocarbamol.
ThalidomideMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Methocarbamol.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methocarbamol.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Methocarbamol.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methocarbamol.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methocarbamol.
TiagabineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Methocarbamol.
TizanidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methocarbamol.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Methocarbamol.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methocarbamol.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Methocarbamol.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methocarbamol.
TrazodoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Methocarbamol.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methocarbamol.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methocarbamol.
TrimipramineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Methocarbamol.
VigabatrinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Methocarbamol.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methocarbamol.
ZiconotideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methocarbamol.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Methocarbamol.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Methocarbamol.
ZonisamideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Methocarbamol.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Methocarbamol.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methocarbamol.
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name:
CA1
Uniprot ID:
P00915
Molecular Weight:
28870.0 Da
References
  1. Parr JS, Khalifah RG: Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50. [PubMed:1460006 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23